SCHEMBL6484730

SCHEMBL6484730

CCOc1ccccc1CNc1ccc2oc3ccc(Cl)cc3c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.53
ALDH1A1 P00352 8/20 0.53
GAA P10253 8/20 0.53
L3MBTL1 Q9Y468 6/20 0.53
THRB P10828 6/20 0.53
BLM P54132 4/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
ATM Q13315 2/20 0.53
RECQL P46063 1/20 0.53
PLEC Q15149 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
SLC2A1 P11166 1/20 0.49
KDM4E B2RXH2 6/20 0.47
LMNA P02545 4/20 0.47
NPSR1 Q6W5P4 4/20 0.47
HTT P42858 2/20 0.47
ALOX12 P18054 2/20 0.47
XBP1 P17861 1/20 0.47
EGFR P00533 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483861 0.89 MAPT (0.56) MAPTALDH1A1GAAL3MBTL1THRB
SCHEMBL6481732 0.87 MAPT (0.54) MAPTALDH1A1GAAL3MBTL1THRB
SCHEMBL6498257 0.82 PPARG (0.51) MAPTALDH1A1GAAL3MBTL1MEN1
SCHEMBL6495210 0.79 MEN1 (0.62) MAPTALDH1A1GAAL3MBTL1MEN1
SCHEMBL6498436 0.79 UTS2R (0.45) MAPTALDH1A1L3MBTL1THRBMEN1
SCHEMBL6768296 0.78 MAOB (0.45) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6483711 0.77 KDM4E (0.55) MAPTALDH1A1GAAL3MBTL1MEN1
SCHEMBL6483858 0.76 IDH1 (0.40) MAPTMEN1KMT2AEGFRTP53
SCHEMBL6483043 0.76 CYP2C9 (0.48) MAPTALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL6495487 0.76 MAOB (0.49) MAPTALDH1A1GAAL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885ALDH1A1 4486/4885GAA 1524/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885ALDH1A1 4111/4885GAA 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.